CONMED (CNMD)
(Delayed Data from NYSE)
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
ResMed's (RMD) Q3 Earnings Beat Estimates, Revenues in Line
by Zacks Equity Research
ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.
Teleflex (TFX) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Teleflex (TFX) reports robust improvement in revenues on balanced growth across all segments and geographies.
Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered
by Zacks Equity Research
Cardiovascular Systems (CSII) rides high on a year-over-year rise in both Coronary and peripheral device revenues.
NuVasive (NUVA) Q1 Earnings Top Estimates, Margins Strong
by Zacks Equity Research
NuVasive's (NUVA) solid international sales in Q1 boost investor confidence in the stock.
DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.
AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) Q2 earnings gain from solid segmental performance and higher adjusted operating income growth. But contraction in adjusted gross and operating margins remains a dampener.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q1
by Zacks Equity Research
At Home Health and Hospice divisions, Amedisys (AMED) witnesses solid year-over-year growth in Medicare and non-Medicare revenues.
ABIOMED (ABMD) Q4 Earnings Meet Estimates, Sales Rise in Japan
by Zacks Equity Research
ABIOMED's (ABMD) Q4 results gain from solid Impella show in Japan.
Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.
CVS Health's (CVS) Q1 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Year-over-year growth in CVS Health's (CVS) top line is aided by a strong Pharmacy Services segment, benefiting from the upside in specialty services.
IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up
by Zacks Equity Research
Strong sales at the CAG business favor IDEXX's (IDXX) top line in Q1.
Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.
LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates
by Urmimala Biswas
Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.
Chemed (CHE) Q1 Earnings Miss Estimates, Revenues Grow Y/Y
by Zacks Equity Research
Despite several downsides, Chemed (CHE) witnesses solid revenue growth across key subsidiaries - VITAS and Roto-Rooter.
Ecolab (ECL) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Ecolab (ECL) gains from core Global Industrial and Global Institutional segments in Q1.
Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q2
by Zacks Equity Research
The strong Q2 performance of Hill-Rom (HRC) is backed by solid core revenue growth, continued margin expansion and strategic investments.
Zimmer Biomet's (ZBH) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
While sales in Americas remains dull, Zimmer Biomet (ZBH) is witnessing strength in the Asia Pacific and EMEA regions.
Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.
Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.
GNC Holdings (GNC) Reports Q1 Earnings, Revenues Down Y/Y
by Zacks Equity Research
Despite year-over-year decline in earnings and revenues, better performing International segment and key developments favor GNC Holdings (GNC) in Q1.
PerkinElmer (PKI) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
PerkinElmer's (PKI) Q1 earnings gain from top-line growth, solid show by Diagnostics segment and strong margins. However, negative currency movement remains a headwind.
Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.
Cerner (CERN) Earnings and Revenues Meet Estimates in Q1
by Zacks Equity Research
Cerner (CERN) gains from Professional Services unit in first-quarter 2019. A decline in bookings raises concern.
CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.